Springer Nature
Browse
13045_2019_827_MOESM3_ESM.docx (128.08 kB)

MOESM3 of Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma

Download (128.08 kB)
journal contribution
posted on 2019-12-06, 04:44 authored by Liwei Lang, Chloe Shay, Xiangdong Zhao, Yuanping Xiong, Xuli Wang, Yong Teng
Additional file 3: Figure S3. The effect of indicated treatment on other Src-related proteins (including STAT3, FAK and EGFR) in HNSCC cells.

Funding

National Institute of Dental and Craniofacial Research

History

Usage metrics

    Journal of Hematology & Oncology

    Categories

    Keywords

    HNSCCSrc, AKTSaracatinibCapivasertibCo-delivery nanoparticlesSynergistic effects

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC